Bladder Cancer

Bladder cancer begins in bladder tissue and is treated according to its depth, spread and cell features.

Most bladder cancers arise in the urothelial cells lining the inside of the bladder. A key distinction is whether tumour cells remain in the inner layers or have grown into the bladder muscle. That distinction shapes treatment, follow-up and the chance of the cancer returning.

Bladder cancer commonly presents with blood in the urine, which may look pink, red or brown and may come and go. Some people develop burning, urgency, frequent urination or difficulty passing urine. Bladder cancer can also cause pelvic or back pain when more advanced, but these symptoms have many non-cancerous explanations.

Visible blood in urine needs timely medical assessment even when it happens once or causes no pain. Seek urgent care if you cannot pass urine, are passing clots with worsening pain, feel faint, or have heavy ongoing bleeding.

Bladder cancer forms when genetic damage allows a bladder cell to grow and divide without normal control. Harmful substances filtered from the blood can become concentrated in urine and remain in contact with the bladder lining. Usually, no single exposure can be identified as the complete cause in an individual.

Non-muscle-invasive disease is confined to the inner bladder layers, while muscle-invasive disease has entered the muscular wall. Grade describes how abnormal the cells look and helps indicate their likely behaviour. Staging also checks nearby lymph nodes and distant organs. Even an early tumour can recur, so scheduled bladder checks are an important part of care.

Tobacco exposure is an important preventable risk factor. Risk may also rise with older age, long-term workplace exposure to certain chemicals, chronic bladder irritation, particular previous cancer treatments and some family or inherited conditions. A risk factor changes probability; it does not establish that cancer is present.

Assessment may include a urine test, blood tests and imaging of the urinary tract. During cystoscopy, a clinician passes a thin viewing instrument through the urethra to inspect the bladder lining. Suspicious tissue is removed or sampled so a pathologist can identify the cancer type, grade and invasion depth.

Further scans may examine the bladder wall, lymph nodes and other organs. The final plan combines pathology and imaging results rather than relying on symptoms alone.

Tumours limited to the inner bladder can often be removed through the urethra. Intravesical BCG therapy or medicine placed directly into the bladder may then reduce recurrence or progression risk for selected tumours. Regular cystoscopy checks can detect new growth early.

Muscle-invasive disease may be treated with bladder removal surgery, often with chemotherapy given around the operation. Bladder-preserving treatment can combine tumour removal, chemotherapy and radiotherapy for suitable people. Immunotherapy or other systemic medicines may be used when the disease is advanced, returns, or has particular biological features.

Care after treatment may involve repeated cystoscopy, urine tests and scans. Discuss urinary frequency, leakage, sexual health, fatigue and emotional strain early because practical support is available. After bladder removal, specialist nurses teach care of a urinary stoma or internal urinary reconstruction. Report new visible bleeding, inability to pass urine, fever or worsening pain without waiting for a routine visit.